(TDOC) Teladoc - Overview
Stock: Virtual Care, Telehealth Platform, Chronic Management, Online Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.6% |
| Relative Tail Risk | -6.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.22 |
| Alpha | -75.51 |
| Character TTM | |
|---|---|
| Beta | 1.469 |
| Beta Downside | 1.212 |
| Drawdowns 3y | |
|---|---|
| Max DD | 85.20% |
| CAGR/Max DD | -0.53 |
Description: TDOC Teladoc January 18, 2026
Teladoc Health, Inc. (NYSE:TDOC) is a U.S.-based provider of virtual healthcare services that operates under the Teladoc, Livongo, and BetterHelp brands. The firm serves a broad client base-including employers, health plans, hospitals, health systems, and individual members-through two primary segments: Integrated Care and BetterHelp.
The Integrated Care segment delivers a suite of telemedicine offerings such as general and specialty medical consultations, chronic-condition management, and enterprise telehealth platforms for health systems. The BetterHelp segment runs an online mental-health marketplace that connects licensed clinicians with users via web, mobile, phone, and text interfaces.
In FY 2023 the company generated approximately $2.5 billion in revenue, down about 10 % year-over-year, while reporting a net loss of $300 million and an adjusted EBITDA margin of roughly 2 %. As of Q4 2023, Teladoc’s active member count hovered near 15 million, with a churn rate that has been trending upward amid intensified competition from both traditional health systems and newer digital-health entrants.
Key drivers of Teladoc’s outlook include (1) employer-driven cost-containment initiatives that increasingly favor virtual-first care models, (2) evolving reimbursement policies-particularly the potential rollback of telehealth parity laws that could compress margins, and (3) macro-level adoption trends in the health-care technology sector, where overall telehealth utilization has plateaued after the pandemic surge, suggesting a shift toward a more mature, price-sensitive market.
If you’re looking for a deeper, data-rich valuation framework, consider reviewing the analytical tools and model templates available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -223.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.66 > 1.0 |
| NWC/Revenue: 27.20% < 20% (prev 26.15%; Δ 1.05% < -1%) |
| CFO/TA 0.10 > 3% & CFO 292.5m > Net Income -223.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (175.7m) vs 12m ago 2.44% < -2% |
| Gross Margin: 69.80% > 18% (prev 0.71%; Δ 6909 % > 0.5%) |
| Asset Turnover: 78.92% > 50% (prev 73.39%; Δ 5.53% > 0%) |
| Interest Coverage Ratio: -8.74 > 6 (EBITDA TTM -29.7m / Interest Expense TTM 21.6m) |
Altman Z'' -15.00
| A: 0.24 (Total Current Assets 1.09b - Total Current Liabilities 405.1m) / Total Assets 2.88b |
| B: -5.70 (Retained Earnings -16.41b / Total Assets 2.88b) |
| C: -0.06 (EBIT TTM -188.8m / Avg Total Assets 3.20b) |
| D: -11.06 (Book Value of Equity -16.44b / Total Liabilities 1.49b) |
| Altman-Z'' Score: -29.02 = D |
Beneish M -3.13
| DSRI: 1.01 (Receivables 219.5m/223.5m, Revenue 2.53b/2.59b) |
| GMI: 1.01 (GM 69.80% / 70.82%) |
| AQI: 1.14 (AQ_t 0.60 / AQ_t-1 0.53) |
| SGI: 0.98 (Revenue 2.53b / 2.59b) |
| TATA: -0.18 (NI -223.6m - CFO 292.5m) / TA 2.88b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of TDOC shares?
Over the past week, the price has changed by -8.07%, over one month by -37.38%, over three months by -34.25% and over the past year by -58.15%.
Is TDOC a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 19
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TDOC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.9 | 78.2% |
| Analysts Target Price | 8.9 | 78.2% |
| ValueRay Target Price | 3.1 | -39.1% |
TDOC Fundamental Data Overview February 07, 2026
P/S = 0.332
P/B = 0.626
P/EG = -1.01
Revenue TTM = 2.53b USD
EBIT TTM = -188.8m USD
EBITDA TTM = -29.7m USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.04b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 315.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.16b USD (839.4m + Debt 1.04b - CCE 726.2m)
Interest Coverage Ratio = -8.74 (Ebit TTM -188.8m / Interest Expense TTM 21.6m)
EV/FCF = 5.81x (Enterprise Value 1.16b / FCF TTM 198.7m)
FCF Yield = 17.20% (FCF TTM 198.7m / Enterprise Value 1.16b)
FCF Margin = 7.86% (FCF TTM 198.7m / Revenue TTM 2.53b)
Net Margin = -8.84% (Net Income TTM -223.6m / Revenue TTM 2.53b)
Gross Margin = 69.80% ((Revenue TTM 2.53b - Cost of Revenue TTM 763.5m) / Revenue TTM)
Gross Margin QoQ = 70.12% (prev 69.85%)
Tobins Q-Ratio = 0.40 (Enterprise Value 1.16b / Total Assets 2.88b)
Interest Expense / Debt = 0.43% (Interest Expense 4.53m / Debt 1.04b)
Taxrate = 21.0% (US default 21%)
NOPAT = -149.2m (EBIT -188.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.70 (Total Current Assets 1.09b / Total Current Liabilities 405.1m)
Debt / Equity = 0.75 (Debt 1.04b / totalStockholderEquity, last quarter 1.39b)
Debt / EBITDA = -10.64 (negative EBITDA) (Net Debt 315.8m / EBITDA -29.7m)
Debt / FCF = 1.59 (Net Debt 315.8m / FCF TTM 198.7m)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.98% (Net Income -223.6m / Total Assets 2.88b)
RoE = -15.60% (Net Income TTM -223.6m / Total Stockholder Equity 1.43b)
RoCE = -7.78% (EBIT -188.8m / Capital Employed (Equity 1.43b + L.T.Debt 994.0m))
RoIC = -5.52% (negative operating profit) (NOPAT -149.2m / Invested Capital 2.70b)
WACC = 5.24% (E(839.4m)/V(1.88b) * Re(11.33%) + D(1.04b)/V(1.88b) * Rd(0.43%) * (1-Tc(0.21)))
Discount Rate = 11.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.86%
[DCF Debug] Terminal Value 87.50% ; FCFF base≈240.1m ; Y1≈272.5m ; Y5≈371.4m
Fair Price DCF = 59.82 (EV 10.93b - Net Debt 315.8m = Equity 10.62b / Shares 177.5m; r=5.90% [WACC]; 5y FCF grow 15.71% → 2.90% )
EPS Correlation: 52.04 | EPS CAGR: 0.53% | SUE: 2.99 | # QB: 1
Revenue Correlation: 61.19 | Revenue CAGR: 3.32% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.27 | Chg30d=+0.027 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.86 | Chg30d=+0.014 | Revisions Net=+1 | Growth EPS=+13.1% | Growth Revenue=+1.0%